Esophageal Cancer Pipeline Assessment 2024: Therapies, Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech, OncoTherapy

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Esophageal Cancer pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Esophageal Cancer Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Esophageal Cancer Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years.

*
Esophageal Cancer companies working in the treatment market are CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others, are developing therapies for the Esophageal Cancer treatment

*
Emerging Esophageal Cancer therapies in the different phases of clinical trials are- CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.

*
In March 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA Registered (tislelizumab-jsgr) as a standalone treatment for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not involve a PD-(L)1 inhibitor. TEVIMBRA is expected to be accessible in the U.S. market during the latter half of 2024.

*
In February 2024, Elevation Oncology, Inc. (Nasdaq: ELEV), a forward-thinking oncology company dedicated to developing targeted cancer therapies for patients with various solid tumors and significant unmet needs, has announced the expansion of its ongoing Phase 1 clinical trial of EO-3021 beyond the United States. The first patient has been dosed in Japan. The trial aims to assess the safety, tolerability, and initial anti-tumor effects of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors that are likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, and esophageal cancers.

Esophageal Cancer Overview

Esophageal cancer is a type of cancer that forms in the esophagus, the long tube that carries food from the throat to the stomach. It typically develops in two main types: squamous cell carcinoma, which occurs in the cells lining the esophagus, and adenocarcinoma, which starts in the mucus-secreting glands of the esophagus. Risk factors include smoking, heavy alcohol use, acid reflux (gastroesophageal reflux disease or GERD), obesity, and certain dietary habits. Symptoms may include difficulty swallowing, weight loss, chest pain, and persistent heartburn. Treatment options often include surgery, chemotherapy, and radiation, depending on the stage of the disease. Early detection is crucial for improving survival rates.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight [https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:

*
CDR404: CDR-Life Inc.

*
M1231: Merck KGaA

*
Sotigalimab: Apexigen

*
Amivantamab: Genmab

*
Telomelysin: Oncolys BioPharma Inc

*
Tiragolumab: Genentech

*
S-588410: Onco Therapy Science, Inc. /Shionogi & Co., Ltd.

*
CS1001: CStone Pharmaceuticals

*
Durvalumab: Celgene/MedImmune

*
Tucatinib: Seagen

*
APX 005M: Apexigen

*
Erdafitinib: Janssen Research & Development, LLC

*
Margetuximab: MacroGenics

*
AN-0025: Adlai Nortye

Esophageal Cancer Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Esophageal Cancer Molecule Type

Esophageal Cancer Products have been categorized under various Molecule types, such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment

*
Esophageal Cancer Assessment by Product Type

*
Esophageal Cancer By Stage and Product Type

*
Esophageal Cancer Assessment by Route of Administration

*
Esophageal Cancer By Stage and Route of Administration

*
Esophageal Cancer Assessment by Molecule Type

*
Esophageal Cancer by Stage and Molecule Type

DelveInsight's Esophageal Cancer Report covers around 100+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Esophageal Cancer Therapeutics Market include:

Key companies developing therapies for Esophageal Cancer are - Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:

The Esophageal Cancer pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.

*
Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Esophageal Cancer Pipeline Market Drivers

*
Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers

*
However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight

*
Coverage: Global

*
Key Esophageal Cancer Companies: CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others

*
Key Esophageal Cancer Therapies: CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others

*
Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies

*
Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Esophageal Cancer Report Introduction

2. Esophageal Cancer Executive Summary

3. Esophageal Cancer Overview

4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Esophageal Cancer Pipeline Therapeutics

6. Esophageal Cancer Late Stage Products (Phase II/III)

7. Esophageal Cancer Mid Stage Products (Phase II)

8. Esophageal Cancer Early Stage Products (Phase I)

9. Esophageal Cancer Preclinical Stage Products

10. Esophageal Cancer Therapeutics Assessment

11. Esophageal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Esophageal Cancer Key Companies

14. Esophageal Cancer Key Products

15. Esophageal Cancer Unmet Needs

16 . Esophageal Cancer Market Drivers and Barriers

17. Esophageal Cancer Future Perspectives and Conclusion

18. Esophageal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-pipeline-assessment-2024-therapies-clinical-trials-latest-fda-ema-and-pmda-approvals-clinical-trials-and-treatment-outlook-oncolys-biopharma-inc-genentech-oncotherapy]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.